Enterin Overview

  • Founded
  • 2016

Founded
  • Status
  • Private

  • Employees
  • 25

Employees
  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $30.7M

  • Investors
  • 3

Enterin General Information

Description

Developer of a novel drug designed to offer novel treatments that target the gut-brain axis and modify the course of neurodegenerative disorders. The company aims to displace α-synuclein aggregates and restore normal signaling between the gut and the brain, enabling clinicians to understand how to delay the aging process, prevent neurodegeneration, and eventually prolong the lifespan of patients with these diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Primary Office
  • 2005 Market Street
  • Suite 3125
  • Philadelphia, PA 19103
  • United States
+1 (215) 000-0000

Enterin Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Enterin Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC 12-Sep-2022 $30.7M 000.00 Completed Clinical Trials - Phase 2
5. Later Stage VC (Series C) 14-Sep-2020 000.00 000.00 00000 Completed Clinical Trials - Phase 2
4. Debt - PPP 28-Apr-2020 000.00 Completed Clinical Trials - Phase 2
3. Early Stage VC (Series B) 28-Jan-2019 000.00 000.00 00000 Completed Clinical Trials - Phase 2
2. Early Stage VC (Series A) 10-Jul-2017 $12.7M $12.7M 000.00 Completed Clinical Trials - Phase 2
1. Accelerator/Incubator Completed Startup
To view Enterin’s complete valuation and funding history, request access »

Enterin Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C 0,000,000 00.000000 00 00.00 00.00 00 00.00 0.000
Series B 0,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series A-2 1,865,223 $0.000100 5% $4.56 $4.56 1x $4.56 8.11%
Series A-1 2,846,620 $0.000100 5% $2.91 $2.91 1x $2.91 12.38%
To view Enterin’s complete cap table history, request access »

Enterin Patents

Enterin Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2020324937-A1 Human aminosterol ent-03 compounds, related compositions comprising the same, and methods of using the same Pending 02-Aug-2019 00000000000
CA-3149479-A1 Human aminosterol ent-03 compounds, related compositions comprising the same, and methods of using the same Pending 02-Aug-2019 00000000000
EP-4007764-A1 Human aminosterol ent-03 compounds, related compositions comprising the same, and methods of using the same Pending 02-Aug-2019 00000000000
EP-4007581-A1 Dosing protocols and regimens for aminosterol treatment Pending 02-Aug-2019 000000000
CA-3149480-A1 Human squalamine derivatives, related compositions comprising the same, and methods of using the same Pending 02-Aug-2019 A61K45/06
To view Enterin’s complete patent history, request access »

Enterin Executive Team (8)

Name Title Board Seat Contact Info
David McCullough Co-Chief Executive Officer & Board Member
Denise Barbut MD Co-Founder, Board Member, President and Chief Medical Officer
Katherine Wolf Chief Financial Officer & Board Member
Michael Zasloff Ph.D Co-Founder, Chief Scientific Officer and Board Member
William Kinney Ph.D Co-Founder and Senior Vice President of Research and Development
You’re viewing 5 of 8 executive team members. Get the full list »

Enterin Board Members (10)

Name Representing Role Since
David McCullough Enterin Co-Chief Executive Officer & Board Member 000 0000
David Vogel Self Board Member 000 0000
Donald Munoz Self Board Member 000 0000
Jay Brammer Self Co-Chief Executive Officer & Chairman 000 0000
Katherine Wolf Enterin Chief Financial Officer & Board Member 000 0000
You’re viewing 5 of 10 board members. Get the full list »

Enterin Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Enterin Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Indie Asset Partners Asset Manager Minority 000 0000 000000 0
Scientia Ventures Venture Capital Minority 000 0000 000000 0
Science Center Accelerator/Incubator 000 0000 000000 0
To view Enterin’s complete investors history, request access »